<DOC>
	<DOCNO>NCT00072462</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use either tamoxifen anastrozole may fight breast cancer block use estrogen . It yet know whether tamoxifen effective anastrozole prevent breast cancer surgery ductal carcinoma situ . PURPOSE : This randomized phase III trial study well adjuvant tamoxifen work compare anastrozole treat postmenopausal woman undergone surgery remove ductal carcinoma situ .</brief_summary>
	<brief_title>Adjuvant Tamoxifen Compared With Anastrozole Treating Postmenopausal Women With Ductal Carcinoma In Situ</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy adjuvant tamoxifen v anastrozole , term local control prevention contralateral disease , postmenopausal woman locally excise ductal carcinoma situ . - Compare side effect profile drug patient . Secondary - Compare efficacy drug , accord receptor status primary recurrent cancer patient . - Compare rate breast cancer recurrence growth new contralateral tumor cessation treatment drug patient . - Compare breast cancer mortality patient treat drug . - Compare effect drug cancer , cardiovascular disease , fracture rate , non-breast cancer death patient . - Compare tolerability acceptability side effect experience patient treated drug . OUTLINE : This randomize , double-blind , multicentre study . Patients stratify accord participate centre . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral tamoxifen oral placebo daily . - Arm II : Patients receive oral anastrozole oral placebo daily . In arm , treatment continue 5 year absence disease recurrence unacceptable toxicity . Patients follow annually 5 year 5 year treatment . Peer Reviewed Funded Cancer Research UK . Sponsored Queen Mary University London ACTUAL ACCRUAL : A total 2,980 patient accrue study 9 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis ductal carcinoma situ within past 6 month Locally excise tumorfree margin least 1 mm Hormone receptor status : Estrogen progesterone receptor positive Equal great 5 % positive cell PATIENT CHARACTERISTICS : Age 40 70 Sex Female Menopausal status Postmenopausal , define meeting least 1 follow criterion : Over age 60 Prior bilateral oophorectomy Age 60 uterus AND amenorrhea least past 12 month Age 60 without uterus AND folliclestimulating hormone great 20 IU/L Performance status Not specify Life expectancy At least 10 year Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular No prior deep vein thrombosis No prior transient ischemic attack No prior cerebrovascular accident Pulmonary No prior pulmonary embolism Other No unexplained postmenopausal bleed No cancer within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No concurrent medical condition would preclude study therapy , place patient unusual risk , confound study result No evidence osteoporosis Fragility fracture within spine allow Tscore level great 4 consist 2 fracture Psychologically physically suitable 5 year study therapy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy No prior concurrent tamoxifen use last 6 month unless treatment complete 5 year ago . Women IBISI join trial therapy least 5 year . No prior concurrent raloxifene use last 6 month unless treatment complete 5 year ago . No prior concurrent selective estrogenreceptor modulator use last 6 month unless treatment complete 5 year ago No concurrent systemic estrogenbased hormone replacement therapy , include vaginal estrogen preparation Radiotherapy Not specify Surgery See Disease Characteristics No prior mastectomy No plan prophylactic mastectomy Other At least 3 month since prior unapproved experimental agent No concurrent anticoagulant</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>breast cancer situ</keyword>
</DOC>